Hypertensive Disorders of Pregnancy
Definition
Hypertensive disorders of pregnancy (HDP) is an umbrella term encompassing four entities defined by the timing and features of hypertension (BP ≥140/90 mmHg) in relation to 20 weeks' gestation: (1) chronic hypertension — present before 20 weeks; (2) gestational hypertension — new-onset after 20 weeks without proteinuria/organ damage; (3) preeclampsia/eclampsia — hypertension after 20 weeks with proteinuria and/or organ damage; and (4) preeclampsia superimposed on chronic hypertension — preexisting hypertension with new or worsening proteinuria or systemic features. HDP affect 7.5% of pregnancies but 15.3% of women across their reproductive lives, and are the second leading cause of global maternal mortality (after hemorrhage).
Key Concepts
Epidemiology and Trends
- HDP affect 7.5% per pregnancy; per-woman lifetime incidence 15.3% — the latter better reflects the number of women at risk for future CVD sources/ht-pregnancy-aha-2022 (rating: high)
- CVD (including stroke and cardiomyopathy) accounts for up to 50% of all maternal deaths; pregnancy-related stroke hospitalizations increased >60% from 1994 to 2011 sources/ht-pregnancy-aha-2022 (rating: high)
- Incidence is rising due to advanced maternal age at first pregnancy and increasing prevalence of obesity and cardiometabolic risk factors
- HDP rates have nearly doubled over the past decade sources/prepregnancy-aha-2023 (rating: high)
HDP Classification (4 Types)
| Type | BP Timing | Additional Features |
|---|---|---|
| Chronic hypertension | <20 weeks (or pre-existing) | Primary (90%) or secondary |
| Gestational hypertension | ≥20 weeks | No proteinuria or organ damage |
| Preeclampsia | ≥20 weeks | + proteinuria and/or organ damage |
| Superimposed preeclampsia | <20 weeks (chronic HT) | New proteinuria or systemic features |
Immediate Maternal Complications (Selected Estimates)
- Preeclampsia: mortality aOR 2.6; MI aOR 3.0; stroke aOR 5.7; peripartum cardiomyopathy aOR 3.3 sources/ht-pregnancy-aha-2022 (rating: high)
- Preeclampsia on chronic HT: stroke aOR 7.8
- Eclampsia: stroke aOR 65.9
- HDP generally: peripartum cardiomyopathy aOR 3.2 (White), 4.0 (Black), 3.0 (Hispanic)
Immediate Fetal Complications
- SGA (<10th centile): HDP RR 1.6; preeclampsia OR 1.5
- Stillbirth: HDP RR 1.4; preeclampsia aOR 1.3
- Preterm birth <37w: preeclampsia aOR 3.1; superimposed preeclampsia aOR 4.7
- Placental abruption: preeclampsia aOR 2.3; postpartum hemorrhage: preeclampsia aOR 2.3 sources/ht-pregnancy-aha-2022 (rating: high)
Long-Term Maternal Sequelae
HDP survivors have substantially elevated future cardiovascular and metabolic risk, independent of traditional risk factors:
| Outcome | Key Risk Estimate |
|---|---|
| Hypertension | Preeclampsia OR 11.6; aHR 4.5; 10 years earlier onset |
| Heart failure | HDP HR 2.7; preeclampsia aHR 2.1 |
| Coronary heart disease | HDP aHR 1.9; preeclampsia aHR 2.1 |
| Atrial fibrillation | HDP HR 1.4; preeclampsia aHR 1.7 |
| All stroke | HDP aHR 1.8; preeclampsia aHR 1.9 |
| Vascular dementia | Gestational HT aHR 3.0; preeclampsia aHR 2.4 |
| CKD | Preeclampsia RR 2.3; gestational HT RR 1.5 |
| ESKD | Preeclampsia RR 6.6; gestational HT RR 3.6 |
| VTE | HDP OR 1.5; preeclampsia aHR 1.6 |
| Type 2 diabetes | HDP HR 1.8; preeclampsia aHR 1.8 |
Sources: sources/ht-pregnancy-aha-2022 (rating: high)
- Approximately two-thirds of HDP-associated CVD risk is mediated by established risk factors; remainder reflects HDP-specific pathogenesis (likely endothelial dysfunction and vascular remodeling)
- Women with HDP show accelerated aging: earlier onset of cardiometabolic risk factors, higher multimorbidity burden
Offspring Long-Term Outcomes
- CVD in offspring (severe preeclampsia): aHR 2.3 sources/ht-pregnancy-aha-2022 (rating: high)
- Stroke in offspring: preeclampsia HR 1.9; gestational HT HR 1.4
- Higher BMI (mean 0.36 kg/m²) and higher SBP/DBP in offspring of preeclamptic mothers
BP Measurement and Classification in Pregnancy
- Hypertension in pregnancy defined universally as ≥140/90 mmHg (two readings ≥4 hours apart)
- White coat HT prevalence: 4–30% in pregnancy; associated with higher preeclampsia risk vs normotension (RR 2.4) but lower than sustained HT
- Secondary hypertension: consider if age <35, severe/resistant, no family history, hypokalemia, elevated creatinine, or early-pregnancy albuminuria; OSA increasingly relevant given rising obesity in reproductive-age women
BP Treatment Thresholds — Controversy
- ACOG (US): treat acute HT at ≥160/110 mmHg; goal 120–160/80–105 mmHg (chronic); minimal treatment for non-severe HT
- International consensus (WHO, NICE, ISSHP, ESC): treat at ≥140/90 mmHg; target ≤135/85 mmHg
- Rationale for US conservatism: (1) short duration of pregnancy minimizes long-term benefit; (2) concern for utero-placental compromise from lower BP; (3) antihypertensive teratogenicity concerns
- CHIPS trial: tight control (achieved 133/85 mmHg) vs less tight — halved severe HT; trend toward reduced preterm birth; no adverse fetal outcomes; tighter control also reduced thrombocytopenia/elevated LFTs
- CHAP trial (published 2022, after this statement): confirmed benefit — treating mild chronic HT to <140/90 mmHg reduced composite APO without increasing SGA
- AHA statement position: supports investigating lower thresholds; endorses personalized/informed decision-making, especially in Black women and those with cardiac/renal comorbidities sources/ht-pregnancy-aha-2022 (rating: high)
Pharmacotherapy
First-line (non-severe): labetalol, methyldopa, long-acting nifedipine — no clear superiority among them
Severe acute hypertension: parenteral labetalol, parenteral hydralazine, or oral nifedipine — equivalent per Cochrane review
Avoid: atenolol (fetal growth restriction); ACEi/ARBs/direct renin inhibitors (fetal renal development); MRA/spironolactone (antiandrogenic); nitroprusside
Diuretics: generally avoided antepartum; furosemide RCT demonstrated 60% reduction in persistent postpartum HT (adjusted RR 0.40)
ESC 2024 Pregnancy-Specific Recommendations
(sources/ht-esc-2024, rating: very high)
Treatment threshold: All confirmed HDP (≥140/90 mmHg on two readings) should receive antihypertensive therapy (Class I, C) — lowered from ≥150/95 mmHg in 2018 ESC/ESH. Aligns with WHO/NICE/ISSHP; remains stricter than ACOG ≥160/110 mmHg threshold for non-severe HT.
BP targets: SBP 110–140 mmHg and DBP 70–80 mmHg (Class I, C). Do not lower DBP below 80 mmHg (risk of uteroplacental insufficiency). Targets apply across all HDP types including chronic, gestational, and preeclampsia.
Preferred antihypertensive agents (all Class I, C):
- Oral labetalol 100–200 mg TDS/QDS (max 800 mg/day)
- Oral extended-release (modified-release) nifedipine 10–40 mg OD/BD (preferred calcium channel blocker)
- Oral methyldopa 250–500 mg TDS/QDS (max 3 g/day)
- No single agent demonstrated superior fetal or maternal outcomes; choice guided by tolerability and comorbidity
Contraindicated agents (Class III, C): ACE inhibitors, ARBs, direct renin inhibitors — associated with fetal/neonatal renal failure, oligohydramnios, and skull ossification defects. MRAs/spironolactone — antiandrogenic effects. Beta-1 selective agents (e.g., atenolol) — fetal growth restriction (use labetalol instead).
Acute severe hypertension (≥160/110 mmHg): Parenteral labetalol (first-line), oral/sublingual nifedipine, or IV hydralazine. Target: SBP <160 mmHg within 15–30 min to prevent maternal stroke. IV magnesium sulfate for eclampsia prevention in severe preeclampsia.
Preeclampsia prevention (Class I, A): Low-dose aspirin 100–150 mg/day from 11–14 weeks gestation to 36 weeks for women at high risk (≥1 high-risk factor: prior preeclampsia, chronic HT, diabetes, CKD, autoimmune disease, twin pregnancy; or ≥3 moderate-risk factors). Align with Fetal Medicine Foundation/ASPRE protocol.
Calcium supplementation (Class I, A): 1.5–2 g/day elemental calcium from early pregnancy (12–20 weeks) in women with low dietary calcium intake (<800 mg/day) — reduces preeclampsia risk by 50–60% in calcium-deficient populations.
Post-partum follow-up (Class I, C):
- Continue antihypertensives postpartum; reassess at 3–6 months
- Assess for persistent HT requiring long-term treatment
- Annual BP, eGFR, fasting glucose, and BMI for at least 3 years post-HDP (recognition of elevated lifetime CVD risk)
- Avoid diuretics if breastfeeding (hydrochlorothiazide/furosemide reduce milk production); labetalol, nifedipine, methyldopa, and enalapril are compatible with breastfeeding
sFlt-1 — Shared Mechanistic Link with Peripartum Cardiomyopathy
- The placenta in late gestation abundantly secretes sFlt-1 (soluble fms-like tyrosine kinase 1) — a decoy receptor for VEGF — which is elevated in both preeclampsia and multiple gestations; sFlt-1 drives cardiovascular rarefaction and is now established as a direct trigger of peripartum cardiomyopathy in animal models sources/peripartum-cmp-nejm-2024 (rating: high)
- Subclinical cardiac dysfunction in patients with preeclampsia (even without overt PPCM) correlates with circulating sFlt-1 levels; activin A (another late-gestation placental peptide) also correlates with cardiac dysfunction, including 1 year post-delivery sources/peripartum-cmp-nejm-2024 (rating: high)
- This provides a molecular explanation for why 1/3–1/2 of all PPCM cases co-occur with HDP/preeclampsia — a shared vasculotoxic hormonal mechanism, not merely an epidemiologic co-occurrence
- See entities/Peripartum-Cardiomyopathy for full PPCM management and prognosis
Postpartum HDP
- ~60% of maternal deaths occur in the first year postpartum; HDP remains a leading cause sources/ht-pregnancy-aha-2022 (rating: high)
- Prevalence: up to 8% in women without antepartum HT; up to 50% with prior preeclampsia at 6–12 weeks postpartum
- Endothelial dysfunction and altered cerebrovascular autoregulation persist postpartum — amplifying hypertension risk
- Complications: stroke, seizures, peripartum cardiomyopathy, metabolic dysregulation
- sFlt-1/PlGF ratio rate of rise is independent predictor of persistent postpartum hypertension
- NSAIDs for postpartum analgesia: conflicting data on BP effects; caution with extended use
Preconception Prevention
- Prepregnancy CVH optimization (Life's Essential 8) reduces HDP risk — see concepts/Prepregnancy-Cardiovascular-Health
- Prepregnancy obesity has a population attributable fraction for HDP of 26.5–30.3% sources/prepregnancy-aha-2023 (rating: high)
- Exercise may reduce gestational HT by ~30% and preeclampsia by ~40%; dietary interventions also reduce pregnancy-related weight gain
- Low-dose aspirin (81–150 mg/day from 12–16 weeks): reduces preeclampsia by 10–20% in high-risk women — see concepts/Preeclampsia
Racial Disparities
- Maternal mortality ratio (2016): White 13; American Indian/Alaska Native 30; Black American 41 per 100,000 live births sources/ht-pregnancy-aha-2022 (rating: high)
- HDP disproportionately affects Black, AIAN women; Black women have higher preeclampsia-related severe morbidity and mortality
- Biological factors (genetic variants) may contribute to higher preeclampsia risk in Black women, beyond social determinants alone
- Implicit racial bias in US health care worsens management of severe maternal morbidity in Black and AIAN women
- See entities/Maternal-Health-Disparities
Contradictions / Open Questions
- Treatment threshold: ACOG ≥160/110 vs international ≥140/90 mmHg — CHAP trial results now support tighter control but US guideline update lag remains; optimal treatment target for non-severe HDP not established sources/ht-pregnancy-aha-2022 (rating: high)
- HDP → CVD causality: whether HDP is on the causal pathway to CVD or a marker of shared underlying risk (preexisting endothelial dysfunction) remains unresolved; approximately one-third of HDP-associated CVD risk is not explained by traditional risk factors
- Postpartum treatment targets: no specific trial-informed BP targets for the postpartum period exist; optimal duration/intensity of postpartum antihypertensive therapy unknown
- Long-term offspring neurodevelopment: antihypertensive medication exposure in utero — long-term neurodevelopmental effects poorly studied
- De novo vs recurrent postpartum preeclampsia: distinction between postpartum aggravation of antepartum HDP and truly de novo postpartum preeclampsia is unclear; role of magnesium sulfate for seizure prevention in postpartum setting undefined
- ESC 2024 threshold vs ACOG persistent gap: ESC 2024 now formally recommends treatment at ≥140/90 mmHg for all confirmed HDP — this remains in direct conflict with ACOG's non-severe threshold of ≥160/110 mmHg; the CHAP trial (2022) supports the lower threshold but US guideline revision remains outstanding (sources/ht-esc-2024, rating: very high)
- Aspirin timing and cessation: ESC 2024 recommends aspirin cessation at 36 weeks (bleeding risk before delivery); ACOG and NICE recommend continuation until delivery — no head-to-head trial has compared these cessation strategies (sources/ht-esc-2024, rating: very high)
- Post-partum ACE inhibitor initiation: ESC 2024 permits enalapril (breastfeeding compatible) postpartum, which would be contraindicated antenatally; the transition from antepartum contraindication to postpartum permission requires clear patient counselling to prevent confusion (sources/ht-esc-2024, rating: very high)
Connections
- Related to concepts/Preeclampsia — the most severe and mechanistically complex HDP subtype
- Related to concepts/Adverse-Pregnancy-Outcomes — HDP is the APO most strongly linked to long-term CVD
- Related to concepts/Prepregnancy-Cardiovascular-Health — prepregnancy CVH as modifiable HDP determinant
- Related to entities/Maternal-Health-Disparities — disproportionate HDP burden in Black and AIAN women
- Related to entities/Hypertension — BP management principles; thresholds in pregnancy context
- Related to entities/Heart-Failure — peripartum cardiomyopathy; long-term HF risk post-HDP
- Related to entities/Peripartum-Cardiomyopathy — HDP/preeclampsia co-occurs in 1/3–1/2 of PPCM; shared sFlt-1 vasculotoxic mechanism
- Related to concepts/LQTS-Pregnancy-Management — overlapping maternal CVH risk context